Every day we change lives

Alexion, AstraZeneca Rare Disease, is AstraZeneca’s business unit focused on rare diseases, created after the acquisition of Alexion Pharmaceuticals, Inc in 2021. A leader in the field of rare diseases for more than 30 years, Alexion is dedicated to people suffering from rare diseases and devastating conditions and their families, focusing on the discovery, development, and commercialization of life-changing drugs. Alexion concentrates its research efforts on new molecules and targets in the complement cascade with clinical application in the areas of hematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the world and serves patients in more than 50 countries.

www.alexion.com